Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

RIDGEFIELD, Conn., Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy.

"This FDA Breakthrough Therapy designation provides Boehringer Ingelheim the opportunity to engage in an ongoing dialogue with the FDA  to help expedite the development of volasertib as a potential treatment option for these patients with AML," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, U.S. Regional Medical Director, Boehringer Ingelheim Pharmaceuticals, Inc. "Volasertib is one of many investigational compounds in Boehringer Ingelheim's growing oncology pipeline and is an example of our commitment to exploring treatment approaches with the goal of improving patient outcomes."

The Breakthrough Therapy designation process was established by the FDA in July 2012 and is intended to facilitate and expedite the development and review of drugs for serious or life-threatening conditions if  preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

AML is an aggressive cancer of the bone marrow and blood.2 It accounts for 25 percent of all adult leukemias in the Western world3 and has one of the lowest survival rates of all leukemias.3 In 2013, it is estimated there will be 14,590 new cases of AML diagnosed in the U.S. and 10,370 deaths from the disease.4

AML is primarily a disease of later adulthood; the average age of an AML patient is 65 years.5 A common treatment approach for AML
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the ... Lilly and Company (NYSE: LLY ), Nektar Therapeutics ... ), and Novartis AG (NYSE: NVS ). Free ... http://investor-edge.com/register . On Friday, December 12, 2014, the ... Industrial Average lost 1.79%, to finish the day at 17,280.83, ...
(Date:12/15/2014)... and BOSTON , December ... leading GPCR structure-guided drug discovery and development company, is ... in the United States relating ... these patents in the US significantly strengthens the global ... major pharmaceutical markets. The suite of patents ...
(Date:12/13/2014)... , Dec. 12, 2014 HudsonAlpha Institute ... HiSeq X Ten sequencing system manufactured by Illumina, ... to produce and analyze genomic data faster and ... the Institute,s commitment to research programs for genomics ... X Ten provides unprecedented capacity, speed and accuracy ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
(Date:12/17/2014)... -- As gas prices rose in recent years, so ... In times of gas increases, more people start ... the researchers explained. They examined data gathered between ... number of motorcycle registrations in the United States and ... analysis revealed a strong association between rising gas prices ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Expectant parents ... Food and Drug Administration recommends. Use of ultrasound ... videos is not entirely risk-free, the agency warns. ... any harm due to ultrasound imaging and heartbeat monitors, ... providers is important," Shahram Vaezy, an FDA biomedical engineer, ...
(Date:12/17/2014)... Greater participation in music classes may benefit children,s language ... in the nonprofit Harmony Project, which provides music education ... Over two years, children who actively participated in the ... speech and reading, compared to those with lower levels ... in music classes occurred in the same areas of ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... A recent survey found that the ... impacting skin health and beauty were: “Connections,” “climate,” “career” ... Water and health advocate and radio host Sharon Kleyne ... the survey and the Four C’s.* Kleyne notes, however, ... discussed would benefit from paying attention to one’s daily ...
Breaking Medicine News(10 mins):Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3
... painkillers, other drugs and end up in the ER, CDC ... cause of accidental poisonings among American children can be found ... , Each year in the United States, more than 71,000 ... for unintentional overdoses of prescription and over-the-counter drugs, the researchers ...
... , , RANCHO CORDOVA, ... Blindness America announced today the results of their joint nationwide survey ... five 12 to 17-year-olds have difficulty seeing the classroom whiteboard/chalkboard, with ... noted even though nearly half (45 percent) of the children in ...
... PALM CITY, Fla., Aug. 4 Connectyx Technologies Holdings Group ... Company has formed a partnership with InstantAmber, a leading child ... enable InstantAmber to offer the MedFlash(TM) product to its membership ... gives parents the ability to keep up to date medical ...
... , , SADDLE BROOK, N.J., ... http://www.kessler-rehab.com ) is the only hospital in New ... country to offer amputees the new PROPRIO FOOT(R), a prosthesis ... advanced bionic technology, developed by Ossur, a global leader in ...
... , , GLENWOOD, Ill., Aug. 4 ... personal and environmental radiation monitoring services, today reported financial results for the three ... Fiscal 2009 Third Quarter Highlights , , ... continued global demand for InLight products and increased domestic badge revenues. , ...
... MARKHAM, ON, Aug. 4 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC ... drug delivery technology to develop novel formulations of drugs, ... collaboration agreement with Venturepharm Group (the "Venturepharm") to establish ... China that is expected to be used as a ...
Cached Medicine News:Health News:Medicines Top Source of Kids' Poisonings 2Health News:Medicines Top Source of Kids' Poisonings 3Health News:Medicines Top Source of Kids' Poisonings 4Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 2Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 3Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 4Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 2Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 3Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 2Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 2Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 4Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 6Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 7Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 8Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 9Health News:AlphaRx and Venturepharm Announce Collaboration Agreement 2
Inquire...
Inquire...
Inquire...
... range of 18 Ophthalmic frames created ... producted to the very hightest quality. ... lightweight Titanium and Beta Titanium models, ... of beautifully formed and innovative designs ...
Medicine Products: